Description

FOXO4 10mg × 10 vials

A synthetic senolytic research peptide studied for cellular senescence models, FOXO4-p53 interaction pathways, apoptosis-related mechanisms, DNA-damage response, aging-related cellular dysfunction, tissue homeostasis, and broader longevity research protocols.

Product Overview

Compound: FOXO4 / FOXO4-DRI
Strength: 10 mg per vial
Injection type: Research protocol dependent
Frequency: Research protocol dependent

Reconstitution

Amount in vial: 10 mg
BAC water: 2 mL
Amount per unit: 50 mcg per unit

Research Dose

Protocol dependent.

Notes

FOXO4-DRI is described as a cell-penetrating peptide designed to interfere with the interaction between FOXO4 and p53 in senescent cells. This pathway is studied in relation to cellular senescence, DNA-damage response, apoptosis regulation, and age-associated tissue dysfunction.

Research literature has examined FOXO4-DRI for its potential to selectively target senescent cells by disrupting FOXO4-p53 binding, promoting p53-dependent apoptosis in senescent-cell models, and supporting research into tissue homeostasis during aging and stress-related cellular damage.

FOXO4 is primarily associated with senolytic and longevity research. It should not be treated as a general wellness, cosmetic, or performance peptide.

Most available evidence comes from laboratory and animal research, with limited human-context data. No standard consumer dosing protocol should be assumed.

Use only within appropriate research or professional guidance frameworks.